CN113149996B - 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 - Google Patents

一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 Download PDF

Info

Publication number
CN113149996B
CN113149996B CN202110481054.4A CN202110481054A CN113149996B CN 113149996 B CN113149996 B CN 113149996B CN 202110481054 A CN202110481054 A CN 202110481054A CN 113149996 B CN113149996 B CN 113149996B
Authority
CN
China
Prior art keywords
compound
reaction
room temperature
concentrated
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110481054.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113149996A (zh
Inventor
郑苏欣
谢成英
郑明月
陆晓杰
乔刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Almai Biotechnology Co ltd
Original Assignee
Suzhou Almai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Almai Biotechnology Co ltd filed Critical Suzhou Almai Biotechnology Co ltd
Publication of CN113149996A publication Critical patent/CN113149996A/zh
Application granted granted Critical
Publication of CN113149996B publication Critical patent/CN113149996B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202110481054.4A 2020-05-12 2021-04-30 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途 Active CN113149996B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010399116 2020-05-12
CN2020103991162 2020-05-12

Publications (2)

Publication Number Publication Date
CN113149996A CN113149996A (zh) 2021-07-23
CN113149996B true CN113149996B (zh) 2022-12-20

Family

ID=76872797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110481054.4A Active CN113149996B (zh) 2020-05-12 2021-04-30 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途

Country Status (5)

Country Link
US (1) US20230192703A1 (ja)
EP (1) EP4141004A4 (ja)
JP (1) JP7406008B2 (ja)
CN (1) CN113149996B (ja)
WO (1) WO2021227904A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024067566A1 (zh) * 2022-09-30 2024-04-04 苏州阿尔脉生物科技有限公司 饱和环类衍生物、包含其的药物组合物及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110419A1 (es) * 2008-08-22 2011-07-13 Novartis Ag Compuestos de pirrolo-pirimidina como inhibidores de cdk
NZ627520A (en) 2010-03-10 2015-10-30 Astrazeneca Ab 4-phenyl pyridine analogues as protein kinase inhibitors
US9249151B2 (en) * 2013-08-23 2016-02-02 Boehringer Ingelheim International Gmbh Bis-amido pyridines
WO2016010108A1 (ja) 2014-07-18 2016-01-21 塩野義製薬株式会社 含窒素複素環誘導体およびそれらを含有する医薬組成物
DK3539961T3 (da) * 2015-06-29 2022-01-03 Astrazeneca Ab Polycykliske amidderivativer som cdk9-inhibitorer
WO2018090869A1 (zh) 2016-11-16 2018-05-24 广东东阳光药业有限公司 酰胺衍生物及其在药物中的应用
CN108727363B (zh) 2017-04-19 2020-06-19 劲方医药科技(上海)有限公司 一种新型细胞周期蛋白依赖性激酶cdk9抑制剂
WO2019024876A1 (zh) * 2017-08-04 2019-02-07 上海和誉生物医药科技有限公司 一种具有fgfr4抑制活性的醛基吡啶衍生物、其制备方法和应用
WO2019154177A1 (zh) 2018-02-12 2019-08-15 恩瑞生物医药科技（上海）有限公司 嘧啶类化合物、其制备方法及其医药用途

Also Published As

Publication number Publication date
EP4141004A4 (en) 2023-08-23
WO2021227904A1 (zh) 2021-11-18
CN113149996A (zh) 2021-07-23
JP7406008B2 (ja) 2023-12-26
EP4141004A1 (en) 2023-03-01
US20230192703A1 (en) 2023-06-22
JP2023515729A (ja) 2023-04-13

Similar Documents

Publication Publication Date Title
JP7097358B2 (ja) アルファｖインテグリン阻害剤としての３－置換プロピオン酸
CN109071546B (zh) 作为jak抑制剂的吡唑并[1,5-a]吡嗪-4-基衍生物
TWI680970B (zh) 可做為ｓｕｍｏ活化酵素抑制劑之雜芳基化合物
TWI633092B (zh) 化合物及其作為β-位置ＡＰＰ裂解酶（ＢＡＣＥ）抑制劑之用途
CN112105610A (zh) 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
TWI676618B (zh) 三環化合物
TW201718561A (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
TW201718536A (zh) 可作為ＴＮＦα調節劑之雜環化合物
CN112672791B (zh) 用作ccr6抑制剂的n-取代二氧代环丁烯基氨基-3-羟基-吡啶甲酰胺
US20240165243A1 (en) Egfr degraders and methods of use
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
TW202317564A (zh) Cdk2抑制劑及其製備方法和用途
CN111630051A (zh) 作为法尼醇x受体调节剂的烯烃螺环化合物
CN115335376A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶（btk）及其使用方法
CN114096545A (zh) 新杂环化合物
CN113173924B (zh) 一种作为cdk抑制剂的吡啶乙酰胺类衍生物、其制备方法及用途
CN114805361A (zh) 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途
WO2024006776A1 (en) Estrogen receptor alpha degraders and medical use thereof
TW202104208A (zh) 吡唑基-氨基-嘧啶基衍生物的苯醚和苯胺及其組合物和方法
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
CN113149996B (zh) 一种作为cdk9抑制剂的多环酰胺类衍生物、其制备方法及用途
CN116600808B (zh) 一类作为kras突变体g12c抑制剂的四氢萘啶类衍生物、其制备方法及其应用
CN107428682B (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
CN112812105A (zh) 一种氨基吡啶基氧基吡唑类衍生物及其制备方法和应用
TW202118756A (zh) 作為ｂｃｒ－ａｂｌ抑制劑的雜環化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant